

Invited Mini Review

Integration of metabolomics and transcriptomics in nanotoxicity studies

Tae Hwan Shin^{1,2}, Da Yeon Lee², Hyeon-Seong Lee³, Hyung Jin Park², Moon Suk Jin², Man-Jeong Paik³, Balachandran Manavalan², Jung-Soon Mo^{4,*} & Gwang Lee^{1,2,*}

¹Institute of Molecular Science and Technology, Ajou University, ²Department of Physiology, Ajou University School of Medicine, Suwon 16499, ³College of Pharmacy, Suncheon National University, Suncheon 57922, ⁴Genomic Instability Research Center, Ajou University School of Medicine, Suwon 16499, Korea

Biomedical research involving nanoparticles has produced useful products with medical applications. However, the potential toxicity of nanoparticles in biofluids, cells, tissues, and organisms is a major challenge. The ‘-omics’ analyses provide molecular profiles of multifactorial biological systems instead of focusing on a single molecule. The ‘omics’ approaches are necessary to evaluate nanotoxicity because classical methods for the detection of nanotoxicity have limited ability in detecting minuscule variations within a cell and do not accurately reflect the actual levels of nanotoxicity. In addition, the ‘omics’ approaches allow analyses of in-depth changes and compensate for the differences associated with high-throughput technologies between actual nanotoxicity and results from traditional cytotoxic evaluations. However, compared with a single omics approach, integrated omics provides precise and sensitive information by integrating complex biological conditions. Thus, these technologies contribute to extended safety evaluations of nanotoxicity and allow the accurate diagnoses of diseases far earlier than was once possible in the nanotechnology era. Here, we review a novel approach for evaluating nanotoxicity by integrating metabolomics with metabolomic profiling and transcriptomics, which is termed “metabotranscriptomics”. [BMB Reports 2018; 51(1): 14-20]

INTRODUCTION

Several recent reports suggest breakthrough applications of nanoparticles (NPs) in biomedical and clinical fields (1-4). NPs

*Corresponding authors. Jung-Soon Mo, Tel: +82-31-219-7803; Fax: +82-31-219-7802; E-mail: j5mo@ajou.ac.kr; Gwang Lee, Tel: +82-31-219-4554; Fax: +82-31-219-5049; E-mail: glee@ajou.ac.kr

<https://doi.org/10.5483/BMBRep.2018.51.1.237>

Received 2 September 2017

Keywords: Integrated omics, Metabolomics, Metabotranscriptomics, Nanotoxicity, Profile, Transcriptomics

have unique physiochemical properties because of their size and large surface area-to-volume ratio, rendering them more reactive and thermodynamically unstable than bulk materials (5, 6). Moreover, NPs are easily absorbed and readily interact with the human body when delivered through inhalation, penetration, and ingestion (7, 8). However, issues regarding their toxicity and safety due to adverse biological effects have led to widespread concerns about the possible negative effects of NPs (9, 10). Specifically, NP-induced oxidative stress is difficult to evaluate with classical methods (11, 12). The practical application of NPs requires studies of biological toxicity. However, there are limitations associated with the evaluation of nanotoxicity using traditional methods of analysis because of the complexities at the nanolevel, underscoring the need for advanced omics approaches.

Omics facilitates the collective characterization and quantification of many different molecules, such as DNA, RNA, proteins, lipids, and metabolites, in cells, tissues, organs, and organisms. The last few decades have produced developments in high-throughput technologies for omics, which enabled comprehensive understanding of processes and novel findings in biomedical studies (13-15). Thus, omics approaches address the complexity of biological systems via interpretations using bioinformatics analyses. Rapid developments in nanotechnology and the production of NPs, which are defined as engineered materials measuring less than 100 nm in one dimension, stress the importance of the potential toxicity of NPs (6, 7, 10, 16). The omics approaches including genomics, transcriptomics, proteomics, and metabolomics are used to evaluate nanotoxicity (17-20). However, a single omics approach provides limited insight into the intricate molecular pathways and the complex biological events in cells and organisms (21-23).

The concept of integrated omics was introduced by Dr. Hood, who suggested a systems biology approach based on the combination of different omics data to provide a comprehensive understanding of the multifactorial origins of biological research (24, 25). Palsson *et al.* suggested many approaches to generate multi-omic data sets and reduce the possibility of resource allocation for data generation versus

data curation and integration (26). Integrated omics has been applied to a wide range of complex and intractable problems in biological studies. In particular, integrated omics was shown to facilitate the determination of cytotoxicity, especially nanotoxicity (27, 28) because cytotoxicity induced by NP treatment in cells could not be detected with traditional methods (29-31). Integrated omics provides a more comprehensive overview of the complexities associated with nanotoxicity compared with a single omics approach. Thus, these technologies contribute to expanding the safety evaluation of nanotoxicity and provide accurate diagnoses of diseases compared with the simple and fragmented interpretations using single omics approaches. Here, we divide this review into three sections as follows: (i) omics approaches for nanotoxicity; (ii) recent approaches for metabolomics and transcriptomics in nanotoxicity; and (iii) integration of omics for the analysis of nanotoxicity.

OMICS APPROACHES FOR NANOTOXICITY

Omics approaches provide a better understanding of cellular events by using large-scale data. In particular, high-throughput technologies in omics have enabled the use of large-scale data to generate novel findings related to NP toxicity and mechanisms of action (17-20). Thus, omics tools prevent the use of fragmented data that could lead to inappropriate conclusions about nanotoxicity. Although the molecular technologies for understanding nanotoxicity, stress responses, molecular damage, and varying responses to NPs have advanced in parallel with molecular cell biology and *in vivo* assessments, the traditional approaches for the safety evaluation of new NPs have limitations regarding their potential toxicity. Thus, omics techniques are well suited to evaluate nanotoxicity both *in vitro* and *in vivo* by providing a more comprehensive view than was previously possible.

A systematic understanding of molecular responses in biological systems has been emphasized following the growth in analytic technologies and bioinformatics. Developments in sequencing technologies have allowed researchers to gather genomic and transcriptomic data (genotypic features) with much higher coverage and cost-effectively. In proteomics and metabolomics, advances in NMR and mass spectroscopy enable the analysis of a broader range of the proteome or metabolome (phenotypic features) with high precision and sensitivity (32). However, despite these improvements, single omics approaches have a fundamental "blind spot" in unraveling complex biological responses. For example, even though transcriptomics allows detection of extensive genotypic changes, it may not facilitate the interpretation of nucleic acid modifications in the genome or address issues concerning coverage of repeat-rich regions and low abundance genes, and is thoroughly inadequate for the determination of the actual phenotype (33, 34). In metabolomics, for which one endpoint is the biological phenotype (35), amplification methods are

unavailable for minor metabolites, and a quantitative analysis of a targeted process can only provide a partial representation of an entire metabolic pathway (22). In addition, it is frequently associated with errors and limitations involving the interpretation of causal mechanisms in biological processes (36). The integration of two or more omics methods is highly recommended for a more comprehensive and holistic understanding of biological systems than is possible with a single omics approach.

RECENT APPROACHES FOR METABOLOMICS AND TRANSCRIPTOMICS IN NANOTOXICITY

In this section, we introduce the main omics approaches: metabolomics and transcriptomics and their application to nanotoxicity studies.

Metabolomics

Metabolomics is the comprehensive analysis of chemical processes involving metabolites that drive cellular functions, such as cellular signaling cascades, homeostatic control, energy metabolism, and cell damage (37). Specifically, the metabolome represents the complete set of small-molecule chemicals found in biological fluids, cells, tissues, organisms, and biological samples; the metabolome directly links genotype with phenotype and is most related to the phenotype (35, 38). In contrast to other omics methods, metabolomics has great potential for the analysis and understanding of cellular biological mechanisms affected by NPs because metabolic changes accurately reflect the characteristic changes in biological fluids, cells, and tissues based on the quantitation of metabolome (27, 39-41).

Metabolomic profiling is necessary to evaluate potential toxicity using either nuclear magnetic resonance (NMR) or mass-spectrometry (MS). NMR is an effective tool for the determination of the structure of organic compounds *ab initio* and the quantitative analysis of a broad range of molecules (such as metabolic fingerprinting) in a crude extract without authentic standards (32, 42). In addition, NMR does not depend on hydrophobicity or metabolite dissociation value, and the results are comparatively more reproducible than those derived from MS (43). However, NMR has a relatively low sensitivity (> 1 nmol) and resolution and cannot detect NMR-inactive molecules (32). Thus, there are limitations for the comprehensive analysis of individual constituents within a sample (44). MS ionizes chemical species and sorts the ions based on their mass-to-charge ratio. It is one of the most widely used methods for the ultrasensitive and simultaneous detection of metabolites by coupling with gas or liquid chromatography (45, 46). Although different types of MS have a high sensitivity of detection, the sample preparation process is tedious, and the selectivity for different classes of metabolites has both advantages and complications (43). In particular, metabolomic profiling of the cellular components,

and target tissue metabolic reactions with gas chromatography-mass chromatography (GC/MS), without targeting a single metabolite, provides a better understanding of the biofluids, cells, and clinical conditions (28, 47-51). Thus, metabolomics has been used in nanotoxicity investigations utilizing high-throughput quantitation methods (11, 52). However, a limitation of metabolomics is that it provides consequential data without identifying the pathways of cellular mechanism. However, by integrating it with transcriptomics, a better understanding of subtle effects such as nanotoxicity can be obtained (27, 28).

Transcriptomics

Transcriptomics refers to the set of all RNA molecules in a cell and involves techniques such as microarray analysis and next-generation sequencing (NGS), called RNA-Seq. This technique is widely used to screen the toxicity of related RNA molecules and to elucidate the toxicity mechanisms (53, 54). Biological analytes from environmental, industrial, and drug-induced toxic exposures have been analyzed using transcriptomics (54-61). Moreover, transcriptomics contributes to the comprehensive investigation of cellular responses induced by NPs using bioinformatics software (22). Even though transcriptomics can provide large data from NP-treated cells, they are qualitative and do not establish a direct

relationship with the pathology. Nanotoxicologists are working to overcome these shortcomings of transcriptomics by dovetailing the molecular mechanisms using other omics methods such as proteomics and metabolomics (27, 62). Moreover, metabolomics facilitates the identification of a phenotype based on cellular response and provides quantitative data, to compensate for the limitations of transcriptomics (27).

INTEGRATION OF OMICS FOR ANALYSIS OF NANOTOXICITY

Integration of omics

Integration of genomics, transcriptomics, proteomics, and metabolomics, facilitates a better understanding of the cellular biology because biological systems are dynamic and heterogeneous (21). Dr. Hood was a pioneer in terms of integrating the different data types and comparing them against a model with a focus on interdisciplinary and systems biology (25, 63). Compared with single omics approaches, integrated approaches provide a large volume of accurate information related to pathophysiology (64-68). Here, we describe the integration of transcriptomics with metabolomics in a process called "metabotranscriptomics" for the analysis of nanotoxicity, to allow a comprehensive analysis of the treatment outcomes with NPs.




Fig. 1. Summary diagram comparing conventional methods and metabotranscriptomics approach for the assessment of MNP@SiO₂(RITC)-induced nanotoxicity (27, 29-31). MNPs: MNP@SiO₂(RITC), IP: Intraperitoneal, TEM: transmission electron microscopy.

Metabotranscriptomics for nanotoxicity analysis

The use of NPs in biomedical research, such as in the diagnosis and treatment of diseases, has gained tremendous momentum (1, 7, 69). Recent research has shown that internalized NPs can cause cytotoxicity by inducing reactive oxygen species (ROS) and increasing endoplasmic reticulum (ER) stress (7, 27, 70, 71). Despite increasing research efforts, the underlying mechanisms of NP toxicity are not clearly understood because of limited studies and preliminary stages of research.

Magnetic NPs (MNPs) and MNPs coated with biocompatible compounds, which are defined as single-dimensional particles with magnetic properties, have been investigated in the context of novel applications in biochemistry, biology, medicine, antibody engineering, cell tracking, and imaging tools (72-75). MNPs@SiO₂(RITC) are synthesized MNPs that consist of a cobalt ferrite core, CoFe₂O₄, and a silica shell containing chemically-bound Rhodamine B isothiocyanate (RITC) for cell staining, separation and MRI contrast (76). The cobalt ferrite core and RITC contained within the silica shell contribute to the stability of MNPs@SiO₂(RITC) and prolonged red fluorescence at 540 nm without photobleaching. A study into the tissue distribution of MNPs@SiO₂(RITC) in mice demonstrated their ability to cross the blood-brain barrier (BBB) without inducing functional deficits. Analyses using hematoxylin and eosin (H&E) staining found no abnormal histopathological lesions in organs after the intraperitoneal injection (IP) of MNPs@SiO₂(RITC) into mice (29) (Fig. 1). Moreover, the injection did not induce any clinical changes (growth, body weight, behavior) or alterations in serum biochemical parameters (glucose, cholesterol, creatinine, and the ratio between the concentrations of the enzymes aspartate transaminase and alanine transaminase). In addition, a few *in vitro* studies such as FACS analysis, MTT assay, chromosome aberration assay, and cell cycle assay, failed to detect any toxicity induced by NPs (27, 29-31) (Fig. 1).

Previous studies were confined to the pathophysiological effects of MNPs@SiO₂(RITC). Treatment with MNPs@SiO₂(RITC) yielded 24 metabolites, nine of which were considered to be significantly altered. However, assessment using only metabolomics does not yield convincing data and has low reliability. Integrating the metabolomic profiling with transcriptomics will allow a more sensitive and detailed toxicological evaluation of cellular responses to NPs and identify novel nanotoxicological biomarkers (27). Metabolic profiling of MNPs@SiO₂(RITC)-treated human embryonic kidney 293 (HEK293) cells revealed that changes in amino acids (AAs), organic acids (OAs) and a few metabolites were related to ROS generation (27), which triggered mitochondrial damage (Fig. 1).

The percent compositions and normalized values of AAs and OAs clearly revealed a marked increase in glutamic acid and pyruvate levels, and decrease in other AAs, such as alanine, valine, leucine, isoleucine, proline, and tyrosine, and

other OAs, such as α -ketoglutarate, oxaloacetate, fumarate, and malate, in the group treated with MNPs@SiO₂(RITC) (27). However, there is a limitation associated with linking ROS generation with metabolic changes (Fig. 2A). For the transcriptome, the expression levels of 45 ROS-generation-related genes were altered. Specifically, 26 genes were upregulated and 19 genes were downregulated, and these genes were found to be connected with direct relationships (Fig. 2B). Thus, we combined transcriptomics and metabolomics for these data using Ingenuity Pathway Analysis (IPA Ver. 8.5, Ingenuity Systems, <http://www.ingenuity.com>), which is a web-based bioinformatics software for the identification of biological functions. The datasets of differentially expressed genes and metabolites were combined, to elucidate the interactions




Fig. 2. Bioinformatics of ROS generation using ingenuity pathway analysis (IPA), (A) metabolomics, (B) transcriptomics, and (C) metabotranscriptomics based on a previous report (27). Red and green areas indicate up- and downregulated metabolites, respectively, in cells treated with MNPs@SiO₂(RITC) compared with control cells. Differentially regulated metabolites obtained from the metabolic profile (more than a \pm 20% change) and microarray data (genes with a $>$ 3-fold change) are shown. In the representation of the genetic networks, the red and green colors indicate up- and down-regulated genes, respectively. Network shape indicates categorization of molecules and function. Information pertaining to the corresponding genes can be found in NCBI (<https://www.ncbi.nlm.nih.gov/>).

between differentially expressed genes and altered metabolites (Fig. 2C), and determine biological changes related to ROS generation. The integration of the metabolic profile and transcriptome revealed a direct correlation between the metabolites and genes related to ROS generation. These results demonstrate the importance of metabotranscriptomics for the detailed analyses of nanotoxicity. Although integrated omics approaches facilitate a comprehensive analysis of cellular pathways in biological systems, several new challenges need to be overcome before they can be used in nanotoxicity investigations.

CONCLUSION

Here, we reviewed the cutting-edge metabotranscriptomic approaches for nanotoxicity evaluation. The traditional methods of detection are limited by their ability to measure nanotoxicity. The introduction of advanced tools has led to the integration of omics, especially metabolomic profiling and transcriptomics, to provide extensive information on biological conditions. The technological progress in the molecular diagnostics can pave the way to the development of additional omics techniques. In addition to the integration of transcriptomics and metabolomics, the combination of transcriptomics, genomics, and proteomics in nanotoxicity studies can be used to facilitate the analyses of subtle changes in cellular physiology and molecular biology. Future studies in nanotoxicity will require the integration and multidisciplinary use of omics methods. This integration is expected to produce major advances in toxicity research and encourage the discovery of novel biomarkers for nanotoxicity for a more complete understanding of the effects of NPs in biomedical studies.

ACKNOWLEDGEMENTS

This work was supported by the Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Education, Science and Technology (2015R1D1A1A09060192); Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0093826, 2016R1C1B2016135); and the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2016M3C7A1904392).

CONFLICTS OF INTEREST

The authors have no conflicting interests.

REFERENCES

1. Stark WJ (2011) Nanoparticles in biological systems.

- Angew Chem Int Ed Engl 50, 1242-1258
2. Havel H, Finch G, Strode P et al (2016) Nanomedicines: From Bench to Bedside and Beyond. *AAPS J* 18, 1373-1378
 3. Yang Y and Yu C (2016) Advances in silica based nanoparticles for targeted cancer therapy. *Nanomedicine* 12, 317-332
 4. Deng R, Lin D, Zhu L et al (2017) Nanoparticle interactions with co-existing contaminants: Joint toxicity, bio-accumulation and risk. *Nanotoxicology*, 1-56
 5. Vayssieres L, Chaneac C, Tronc E and Jolivet JP (1998) Size Tailoring of Magnetite Particles Formed by Aqueous Precipitation: An Example of Thermodynamic Stability of Nanometric Oxide Particles. *J Colloid Interface Sci* 205, 205-212
 6. Auffan M, Rose J, Bottero JY, Lowry GV, Jolivet JP and Wiesner MR (2009) Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. *Nat Nanotechnol* 4, 634-641
 7. Krug HF and Wick P (2011) Nanotoxicology: an interdisciplinary challenge. *Angew Chem Int Ed Engl* 50, 1260-1278
 8. Bouallegui Y, Ben Younes R, Bellamine H and Oueslati R (2017) Histopathology and analyses of inflammation intensity in the gills of mussels exposed to silver nanoparticles: role of nanoparticle size, exposure time, and uptake pathways. *Toxicol Mech Methods*, 1-10
 9. Service RF (2000) Is nanotechnology dangerous? *Science* 290, 1526-1527
 10. Boyes WK, Thornton BLM, Al-Abed SR et al (2017) A comprehensive framework for evaluating the environmental health and safety implications of engineered nanomaterials. *Crit Rev Toxicol*, 1-44
 11. Schnackenberg LK, Sun J and Beger RD (2012) Metabolomics techniques in nanotoxicology studies. *Methods Mol Biol* 926, 141-156
 12. Masoud R, Bizouarn T, Trepout S et al (2015) Titanium Dioxide Nanoparticles Increase Superoxide Anion Production by Acting on NADPH Oxidase. *PLoS One* 10, e0144829
 13. Tuncbag N, Gosline SJ, Kedaigle A, Soltis AR, Gitter A and Fraenkel E (2016) Network-Based Interpretation of Diverse High-Throughput Datasets through the Omics Integrator Software Package. *PLoS Comput Biol* 12, e1004879
 14. Norris JL, Farrow MA, Gutierrez DB et al (2017) Integrated, High-Throughput, Multiomics Platform Enables Data-Driven Construction of Cellular Responses and Reveals Global Drug Mechanisms of Action. *J Proteome Res* 16, 1364-1375
 15. Hasin Y, Seldin M and Lusk A (2017) Multi-omics approaches to disease. *Genome Biol* 18, 83
 16. Hu X, Li D, Gao Y, Mu L and Zhou Q (2016) Knowledge gaps between nanotoxicological research and nanomaterial safety. *Environ Int* 94, 8-23
 17. Reyes VC, Li M, Hoek EM, Mahendra S and Damoiseaux R (2012) Genome-wide assessment in *Escherichia coli* reveals time-dependent nanotoxicity paradigms. *ACS Nano* 6, 9402-9415
 18. Bo Y, Jin C, Liu Y, Yu W and Kang H (2014) Metabolomic

- analysis on the toxicological effects of TiO₂ nanoparticles in mouse fibroblast cells: from the perspective of perturbations in amino acid metabolism. *Toxicol Mech Methods* 24, 461-469
19. Verano-Braga T, Miethling-Graff R, Wojdyla K et al (2014) Insights into the cellular response triggered by silver nanoparticles using quantitative proteomics. *ACS Nano* 8, 2161-2175
 20. Zhao Y, Li L, Zhang PF et al (2015) Differential Regulation of Gene and Protein Expression by Zinc Oxide Nanoparticles in Hen's Ovarian Granulosa Cells: Specific Roles of Nanoparticles. *PLoS One* 10, e0140499
 21. Prohaska SJ and Stadler PF (2011) The use and abuse of -omes. *Methods Mol Biol* 719, 173-196
 22. Van Assche R, Broeckx V, Boonen K et al (2015) Integrating -Omics: Systems Biology as Explored Through *C. elegans* Research. *J Mol Biol* 427, 3441-3451
 23. Sun YV and Hu YJ (2016) Integrative Analysis of Multi-omics Data for Discovery and Functional Studies of Complex Human Diseases. *Adv Genet* 93, 147-190
 24. Hood L (2003) Leroy Hood expounds the principles, practice and future of systems biology. *Drug Discov Today* 8, 436-438
 25. Hood L (2003) Systems biology: integrating technology, biology, and computation. *Mech Ageing Dev* 124, 9-16
 26. Palsson B and Zengler K (2010) The challenges of integrating multi-omic data sets. *Nat Chem Biol* 6, 787-789
 27. Shim W, Paik MJ, Nguyen DT et al (2012) Analysis of changes in gene expression and metabolic profiles induced by silica-coated magnetic nanoparticles. *ACS Nano* 6, 7665-7680
 28. Phukan G, Shin TH, Shim JS et al (2016) Silica-coated magnetic nanoparticles impair proteasome activity and increase the formation of cytoplasmic inclusion bodies in vitro. *Sci Rep* 6, 29095
 29. Kim JS, Yoon TJ, Yu KN et al (2006) Toxicity and tissue distribution of magnetic nanoparticles in mice. *Toxicol Sci* 89, 338-347
 30. Park KS, Tae J, Choi B et al (2010) Characterization, in vitro cytotoxicity assessment, and in vivo visualization of multimodal, RITC-labeled, silica-coated magnetic nanoparticles for labeling human cord blood-derived mesenchymal stem cells. *Nanomedicine* 6, 263-276
 31. Beck GR Jr, Ha SW, Camalier CE et al (2012) Bioactive silica-based nanoparticles stimulate bone-forming osteoblasts, suppress bone-resorbing osteoclasts, and enhance bone mineral density in vivo. *Nanomedicine* 8, 793-803
 32. Fan TW, Higashi RM and Lane AN (2006) Integrating metabolomics and transcriptomics for probing SE anticancer mechanisms. *Drug Metab Rev* 38, 707-732
 33. Rehrauer H, Opitz L, Tan G, Sieverling L and Schlapbach R (2013) Blind spots of quantitative RNA-seq: the limits for assessing abundance, differential expression, and isoform switching. *BMC Bioinformatics* 14, 370
 34. Evans TG (2015) Considerations for the use of transcriptomics in identifying the 'genes that matter' for environmental adaptation. *J Exp Biol* 218, 1925-1935
 35. Gibney MJ, Walsh M, Brennan L, Roche HM, German B and van Ommen B (2005) Metabolomics in human nutrition: opportunities and challenges. *Am J Clin Nutr* 82, 497-503
 36. Moseley HN (2013) Error Analysis and Propagation in Metabolomics Data Analysis. *Comput Struct Biotechnol J* 4
 37. Johnson CH, Ivanisevic J and Siuzdak G (2016) Metabolomics: beyond biomarkers and towards mechanisms. *Nat Rev Mol Cell Biol* 17, 451-459
 38. Fukusaki E (2014) Application of Metabolomics for High Resolution Phenotype Analysis. *Mass Spectrom (Tokyo)* 3, S0045
 39. Zlatkis A, Brazell RS and Poole CF (1981) The role of organic volatile profiles in clinical diagnosis. *Clin Chem* 27, 789-797
 40. Karlic H, Thaler R, Gerner C et al (2015) Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells. *Cancer Genet* 208, 241-252
 41. Zabala-Letona A, Arruabarrena-Aristorena A, Martin-Martin N et al (2017) mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. *Nature* 547, 109-113
 42. Robertson DG, Watkins PB and Reily MD (2011) Metabolomics in toxicology: preclinical and clinical applications. *Toxicol Sci* 120 Suppl 1, S146-170
 43. Pan Z and Raftery D (2007) Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. *Anal Bioanal Chem* 387, 525-527
 44. Shah SH, Kraus WE and Newgard CB (2012) Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. *Circulation* 126, 1110-1120
 45. Smith CA, Want EJ, O'Maille G, Abagyan R and Siuzdak G (2006) XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. *Anal Chem* 78, 779-787
 46. Dudley E, Yousef M, Wang Y and Griffiths WJ (2010) Targeted metabolomics and mass spectrometry. *Adv Protein Chem Struct Biol* 80, 45-83
 47. Paik MJ, Lee KA, Park CS et al (2007) Pattern recognition analysis of polyamines in the plasma of rat models with adenovirus infection. *Clin Chim Acta* 380, 228-231
 48. Paik MJ, Li WY, Ahn YH et al (2009) The free fatty acid metabolome in cerebral ischemia following human mesenchymal stem cell transplantation in rats. *Clin Chim Acta* 402, 25-30
 49. Paik MJ, Ahn YH, Lee PH et al (2010) Polyamine patterns in the cerebrospinal fluid of patients with Parkinson's disease and multiple system atrophy. *Clin Chim Acta* 411, 1532-1535
 50. Shin TH, Phukan G, Shim JS et al (2016) Restoration of Polyamine Metabolic Patterns in In Vivo and In Vitro Model of Ischemic Stroke following Human Mesenchymal Stem Cell Treatment. *Stem Cells Int* 2016, 4612531
 51. Shin TH, Lee S, Choi KR et al (2017) Quality and freshness of human bone marrow-derived mesenchymal stem cells decrease over time after trypsinization and storage in phosphate-buffered saline. *Sci Rep* 7, 1106
 52. Lv M, Huang W, Chen Z et al (2015) Metabolomics techniques for nanotoxicity investigations. *Bioanalysis* 7, 1527-1544

53. Vatakuti S, Pennings JL, Gore E, Olinga P and Groothuis GM (2016) Classification of Cholestatic and Necrotic Hepatotoxicants Using Transcriptomics on Human Precision-Cut Liver Slices. *Chem Res Toxicol* 29, 342-351
54. Kohonen P, Parkkinen JA, Willighagen EL et al (2017) A transcriptomics data-driven gene space accurately predicts liver cytopathology and drug-induced liver injury. *Nat Commun* 8, 15932
55. Dix DJ, Gallagher K, Benson WH et al (2006) A framework for the use of genomics data at the EPA. *Nat Biotechnol* 24, 1108-1111
56. Williams TD, Mirbahai L and Chipman JK (2014) The toxicological application of transcriptomics and epigenomics in zebrafish and other teleosts. *Brief Funct Genomics* 13, 157-171
57. Cheng F, Theodorescu D, Schulman IG and Lee JK (2011) In vitro transcriptomic prediction of hepatotoxicity for early drug discovery. *J Theor Biol* 290, 27-36
58. Zhang M, Chen M and Tong W (2012) Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans? *Chem Res Toxicol* 25, 122-129
59. Chen M, Bisgin H, Tong L et al (2014) Toward predictive models for drug-induced liver injury in humans: are we there yet? *Biomark Med* 8, 201-213
60. Chen S, Xuan J, Couch L et al (2014) Sertraline induces endoplasmic reticulum stress in hepatic cells. *Toxicology* 322, 78-88
61. Otava M, Shkedy Z, Talloen W, Verheyen GR and Kasim A (2015) Identification of in vitro and in vivo disconnects using transcriptomic data. *BMC Genomics* 16, 615
62. Lorscheidt S and Lamprecht A (2016) Safety assessment of nanoparticles for drug delivery by means of classic in vitro assays and beyond. *Expert Opin Drug Deliv* 13, 1545-1558
63. Hood L, Rowen L, Galas DJ and Aitchison JD (2008) Systems biology at the Institute for Systems Biology. *Brief Funct Genomic Proteomic* 7, 239-248
64. Shah SH and Newgard CB (2015) Integrated metabolomics and genomics: systems approaches to biomarkers and mechanisms of cardiovascular disease. *Circ Cardiovasc Genet* 8, 410-419
65. Rebollar EA, Antwis RE, Becker MH et al (2016) Using "Omics" and Integrated Multi-Omics Approaches to Guide Probiotic Selection to Mitigate Chytridiomycosis and Other Emerging Infectious Diseases. *Front Microbiol* 7, 68
66. Hartiala JA, Tang WH, Wang Z et al (2016) Genome-wide association study and targeted metabolomics identifies sex-specific association of CPS1 with coronary artery disease. *Nat Commun* 7, 10558
67. Kim J, Woo HR and Nam HG (2016) Toward Systems Understanding of Leaf Senescence: An Integrated Multi-Omics Perspective on Leaf Senescence Research. *Mol Plant* 9, 813-825
68. Berg KCG, Eide PW, Eilertsen IA et al (2017) Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. *Mol Cancer* 16, 116
69. Thakor AS and Gambhir SS (2013) Nanooncology: the future of cancer diagnosis and therapy. *CA Cancer J Clin* 63, 395-418
70. Chen R, Huo L, Shi X et al (2014) Endoplasmic reticulum stress induced by zinc oxide nanoparticles is an earlier biomarker for nanotoxicological evaluation. *ACS Nano* 8, 2562-2574
71. Matysiak M, Kapka-Skrzypczak L, Brzoska K, Gutleb AC and Kruszewski M (2016) Proteomic approach to nanotoxicity. *J Proteomics* 137, 35-44
72. Amemiya Y, Tanaka T, Yoza B and Matsunaga T (2005) Novel detection system for biomolecules using nano-sized bacterial magnetic particles and magnetic force microscopy. *J Biotechnol* 120, 308-314
73. Jun YW, Seo JW and Cheon J (2008) Nanoscaling laws of magnetic nanoparticles and their applicabilities in biomedical sciences. *Acc Chem Res* 41, 179-189
74. Larsen BA, Haag MA, Serkova NJ, Shroyer KR and Stoldt CR (2008) Controlled aggregation of superparamagnetic iron oxide nanoparticles for the development of molecular magnetic resonance imaging probes. *Nanotechnology* 19, 265102
75. Kang T, Li F, Baik S, Shao W, Ling D and Hyeon T (2017) Surface design of magnetic nanoparticles for stimuli-responsive cancer imaging and therapy. *Biomaterials* 136, 98-114
76. Yoon TJ, Kim JS, Kim BG, Yu KN, Cho MH and Lee JK (2005) Multifunctional nanoparticles possessing a "magnetic motor effect" for drug or gene delivery. *Angew Chem Int Ed Engl* 44, 1068-1071